AI & ChatGPT searches , social queries for SETMELANOTIDE
Search references for SETMELANOTIDE. Phrases containing SETMELANOTIDE
See searches and references containing SETMELANOTIDE!
Search references for SETMELANOTIDE. Phrases containing SETMELANOTIDE
See searches and references containing SETMELANOTIDE!SETMELANOTIDE
Chemical compound
Setmelanotide, sold under the brand name Imcivree, is a medication used for the treatment of genetic obesity caused by a rare single-gene mutation. The
Setmelanotide
Chemical compound
intake and lost weight. Another drug with a similar mechanism of action (setmelanotide) is approved for weight loss in rare types of obesity. Bremelanotide
Bremelanotide
Medical condition
include bariatric surgery and melanocortin 4 receptor agonists such as setmelanotide. Dimitri, Paul (6 April 2022). "Treatment of Acquired Hypothalamic Obesity:
Hypothalamic_obesity
Chemical compound
obesity, . Unlike the older drug with the same mechanism of action, setmelanotide, it can be taken orally. As of 9 Feb 2026, Rhythm Pharmaceuticals has
Bivamelagon
Class of pharmacological agents
reducing energy intake or if they also increase energy expenditure. Setmelanotide is an agonist of the melanocortin 4 receptor and is used in people with
Anti-obesity_medication
Ciliopathic recessive genetic disorder
multidisciplinary team manages patients with adequate supportive treatments.Setmelanotide (marketed as Imcivree) was approved for treatment of obesity and the
Bardet–Biedl_syndrome
Family of peptide hormones and neuropeptides
bremelanotide by Palatin Technologies. Others include modimelanotide and setmelanotide. Afamelanotide (brand name Scenesse) has been approved for the treatment
Melanocyte-stimulating hormone
Melanocyte-stimulating_hormone
Drug that never made it to the market
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
Melanotan_II
Obesity caused by a mutation in a single gene
to POMC, PCSK1, or leptin receptor deficiency who were treated with setmelanotide, an MC4R agonist mimicking the POMC-derived alpha-MSH resulted in drastic
Monogenic_obesity
Mammalian protein found in humans
cachexia. The structures of the receptor in complex with the agonist setmelanotide and the antagonist SHU9119 have been determined. The MC4 receptor agonist
Melanocortin_4_receptor
Investigational substance-related disorder drugs
GABAA receptor negative allosteric modulator and neurosteroid [10] Setmelanotide (BIM-22493; CAM-4072; Imcivree; RM-493) – melanocortin MC4 receptor
List of investigational Prader–Willi syndrome drugs
List_of_investigational_Prader–Willi_syndrome_drugs
Mammalian protein found in Homo sapiens
appetite and food intake. In rare cases of POMC deficiency, treatment with setmelanotide, a selective melanocortin-4 receptor agonist, has been effective. Two
Proopiomelanocortin
Protein controlling mammalian coloration
peptide full agonist Modimelanotide - nonselective peptide full agonist Setmelanotide - nonselective peptide full agonist Agouti signalling peptide - nonselective
Melanocortin_1_receptor
Pharmaceutical compound
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
Atumelnant
Chemical compound
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
Semax
Pharmaceutical compound
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
Volufralin
Pharmaceutical compound
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
RO-0282425
Peptides derived from pro-opiomelanocortin
premenopausal women. At therapeutic dose levels, it activates MC1R and MC4R. Setmelanotide (Imcivree) is an MC4R agonist approved for chronic weight management
Melanocortin
Chemical compound
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
THIQ
Experimental erectile dysfunction drug
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
PF-00446687
Chemical compound
pursued. Afamelanotide BMS-470,539 Bremelanotide Melanotan II PF-00446687 Setmelanotide Ramos AM, González-Guerrero C, Sanz A, Sanchez-Niño MD, Rodríguez-Osorio
Modimelanotide
Chemical compound
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
Afamelanotide
Pituitary hormone
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
Adrenocorticotropic_hormone
Chemical compound
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
SNAP-7941
G protein-coupled receptor
β-MSH γ-MSH Afamelanotide Bremelanotide Melanotan II Modimelanotide Setmelanotide MC1-selective BMS-470,539 MC4-selective PF-00446687 PL-6983 THIQ Unknown
Melanocortin_receptor
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
N-Terminal peptide of proopiomelanocortin
N-Terminal_peptide_of_proopiomelanocortin
Obesity in children
was associated with a reduced risk for suicidal ideation or attempt. Setmelanotide is approved for children six years or older with certain types of secondary
Childhood_obesity
Protein-coding gene in mammals
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
Agouti-signaling_protein
Pharmaceutical drug classification
Clobenzorex A08AA09 Mefenorex A08AA10 Sibutramine A08AA11 Lorcaserin A08AA12 Setmelanotide A08AA51 Phentermine and topiramate A08AA56 Ephedrine, combinations A08AA62
ATC_code_A08
System involved in the regulation of weight and peripheral tissue such as hair and skin
are a target of choice for anti-obesity drugs development, such as setmelanotide and lorcaserin, but also diabetes, cachexia and eating disorders such
Central_melanocortin_system
Chemical compound
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
Adrenocorticotropic hormone (medication)
Adrenocorticotropic_hormone_(medication)
American biochemist, pharmaceutical scientist, and entrepreneur
Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019 | Rhythm Pharmaceuticals
Louis_Tartaglia
Mammalian protein found in Homo sapiens
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
Agouti-related_peptide
Chemical compound
pharmacodynamic profile. Afamelanotide Bremelanotide Melanotan II Modimelanotide Setmelanotide Kang L, McIntyre KW, Gillooly KM, et al. (October 2006). "A selective
BMS-470539
IDH1 mutation Baricitinib Eli Lilly and Company severe alopecia areata Setmelanotide Rhythm Pharmaceuticals Bardet–Biedl syndrome Dextromethorphan/bupropion
List of drugs granted breakthrough therapy designation
List_of_drugs_granted_breakthrough_therapy_designation
Chemical compound
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
PL-6983
Peptide hormone in mammals
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
Α-Melanocyte-stimulating hormone
Α-Melanocyte-stimulating_hormone
Mammalian protein found in humans
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
Melanocortin_3_receptor
Chemical compound
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
Alsactide
Chemical compound
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
Β-Melanocyte-stimulating hormone
Β-Melanocyte-stimulating_hormone
Mammalian protein found in humans
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
ACTH_receptor
Chemical compound
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
Γ-Melanocyte-stimulating hormone
Γ-Melanocyte-stimulating_hormone
Protein found in humans
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
Melanocortin_5_receptor
Pharmaceutical compound
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
Libiguin_A
Pharmaceutical compound
Modimelanotide PF-00446687 (PF-446687) PG-931 PL-6983 Ro 27-3225 RO-0282425 Setmelanotide THIQ Indirect agonists Libiguin A Libiguin B Volufralin (LIB-01; DIC-2024;
Mifomelatide
SETMELANOTIDE
SETMELANOTIDE
SETMELANOTIDE
SETMELANOTIDE
SETMELANOTIDE
SETMELANOTIDE
SETMELANOTIDE
SETMELANOTIDE
SETMELANOTIDE